Edition:
United States

Daiichi Sankyo Co Ltd (4568.T)

4568.T on Tokyo Stock Exchange

2,850JPY
1:00am EST
Change (% chg)

¥6 (+0.23%)
Prev Close
¥2,844
Open
¥2,848
Day's High
¥2,857
Day's Low
¥2,828
Volume
2,388,800
Avg. Vol
2,505,916
52-wk High
¥2,857
52-wk Low
¥2,284

Latest Key Developments (Source: Significant Developments)

Daiichi Sankyo and unit says settlement agreement on u.s. products liability litigation
Tuesday, 1 Aug 2017 10:26pm EDT 

Aug 2 (Reuters) - Daiichi Sankyo Co Ltd <4568.T>:* Says it and U.S.-based unit Daiichi Sankyo, Inc. have agreed to enter into a program to settle, on behalf of all defendants, pending product liability litigation against various Daiichi Sankyo and Forest entities .* According to the settlement agreement, it and unit will pay settlement fund of $300 million to plaintiffs.  Full Article

Daiichi Sankyo announces settlement on U.S. products liability litigation
Tuesday, 1 Aug 2017 12:14pm EDT 

Aug 1 (Reuters) - Daiichi Sankyo Co Ltd <4568.T>::Announces settlement agreement on U.S. Products liability litigation​.Impact to financial position of company is not considered material from agreement​.Claimants who meet specified criteria will receive payouts from settlement fund, which is capped at $300 million.  Full Article

EU Medicines Agency recommends approval of Novartis' leukaemia drug
Friday, 21 Jul 2017 07:37am EDT 

July 21 (Reuters) - EU Medicines Agency: :EU Medicines Agency recommendations For July 2017.EU Medicines Agency recommends approval of Pfizer Inc and Merck KGAA Avelumab drug for cell carcinoma‍​.EU Medicines Agency recommends approval of Sanofi and Regeneron Dupixent drug for severe eczema.EU Medicines Agency recommends approval Of Roche Tecentriq drug for drug for bladder and lung cancer‍​.EU Medicines Agency recommends approval Of Advanced Accelerator Applications Lutathera drug for gastroenteropancreatic neuroendocrine tumours.EU Medicines Agency recommends against approval of Nektar Therapeutics and Daiichi Sankyo Onzeald drug for breast cancer.EU Medicines Agency recommends approval of Novartis Rydapt drug for leukaemia.  Full Article

C&Kim buys 10.6 pct stake in HansolNexG
Monday, 3 Jul 2017 11:04pm EDT 

July 4 (Reuters) - HansolNexG Co Ltd <081970.KQ> ::* Says C&Kim Co Ltd has acquired 613,100 shares of the co, and is holding 10.6 percent stake in the co, from 0 percent stake .  Full Article

Daiichi Sankyo announces top-line results from phase 3 global clinical development program evaluating mirogabalin in pain syndromes
Friday, 30 Jun 2017 07:00am EDT 

June 30 (Reuters) - Daiichi Sankyo Co Ltd <4568.T>:Daiichi Sankyo announces top-line results from phase 3 global clinical development program evaluating mirogabalin in pain syndromes.Daiichi Sankyo Co Ltd - Preliminary and ongoing analyses indicated no unexpected safety concerns in neucourse or alday clinical trials.Daiichi Sankyo Co Ltd - In phase 3 alday clinical trials, mirogabalin did not meet primary efficacy endpoint.Says ‍in neucourse, mirogabalin met primary efficacy endpoint​.  Full Article

Daiichi Sankyo to invest 22 bln yen in U.S. for Luitpold Pharmaceuticals - Nikkei
Wednesday, 24 May 2017 04:30pm EDT 

May 25 (Reuters) - Nikkei::Daiichi Sankyo to invest 22 billion yen in U.S. for Luitpold Pharmaceuticals; targets about 70 pct rise in Luitpold's sales to 150 billion yen in fiscal 2020 versus 2015 - Nikkei.  Full Article

Daiichi Sankyo makes 15 bln yen investment
Thursday, 27 Apr 2017 08:00am EDT 

April 27 (Reuters) - Daiichi Sankyo Co Ltd <4568.T>::Daiichi Sankyo - making initial 15 billion yen investment to optimize and enhance manufacturing capabilities to support growing antibody drug conjugate pipeline.  Full Article

GSK seeks Japanese approval for shingles vaccine
Tuesday, 18 Apr 2017 04:16am EDT 

April 18 (Reuters) - GlaxoSmithKline Plc ::Gsk vaccine submission for shingles in japan.JV between GSK, Daiichi Sankyo submitted new drug application in Japan seeking approval for candidate shingles vaccine, shingrix.  Full Article

HTG Molecular says entered into master services agreement with Daiichi Sankyo Company
Monday, 17 Apr 2017 07:30am EDT 

April 17 (Reuters) - Htg Molecular Diagnostics Inc :Htg molecular diagnostics - entered into master services agreement with daiichi sankyo company, ltd for work to be performed in htg's veri/o laboratory.Htg molecular diagnostics - initial project includes development of custom assay for detection of nearly 3,000 mrna targets using htg edgeseq technology.  Full Article

Sosei Group unit signs alliance for R & D of new small molecule therapeutic drug with DAIICHI SANKYO COMPANY LIMITED.
Monday, 13 Mar 2017 03:16am EDT 

Sosei Group Corp <4565.T>:Says its subsidiary Heptares signed an alliance for R & D of new small molecule therapeutic drug with DAIICHI SANKYO COMPANY LIMITED. on March 13.  Full Article

BRIEF-Vernalis has entered into drug discovery collaboration with Daiichi Sankyo

* VERNALIS SAYS ‍HAS ENTERED INTO DRUG DISCOVERY COLLABORATION WITH DAIICHI SANKYO COMPANY, LIMITED UTILIZING VERNALIS' DRUG DISCOVERY PLATFORM​